This is genuinely debated among experts, and it depends heavily on timing and the exact hormones used.

The original large trial (WHI) found a small increase in heart disease events in women who started hormone therapy years past menopause (average age 63). Newer analyses suggest women who start within about 10 years of menopause may not carry that same risk and could see a more favorable pattern, but no guideline currently recommends hormone therapy specifically to prevent heart disease. It remains a therapy for symptoms and bone protection, with the cardiovascular picture being reassuring for younger, recently menopausal starters rather than a proven protective use.

What to know about this answer

This is the single most contested question in the whole hormone-therapy field. Guideline bodies say the WHI, the largest randomized dataset ever collected, never proved a heart-protective effect even in younger women. A group of field experts and lipid researchers argue the totality of evidence, including subgroup data, one small open-label trial, and decades of observational data, does support real protection when therapy starts early.

What the research shows, and which source each finding rests on

WHI 2002 principal results (CEE+MPA, mean age 63): CHD HR 1.29; absolute excess of about 7 more CHD events per 10,000 person-years; all-cause mortality unaffected (HR 0.98).

B[1]

WHI estrogen-alone trial (hysterectomized women): CHD HR 0.91, no increase.

B[2]

Age/time-since-menopause gradient in WHI: women randomized less than 10 years after menopause had CHD HR 0.76 (0.50-1.16); 10-19 years, HR 1.10; 20+ years, HR 1.28 (p trend = 0.02). Stroke risk was elevated regardless of timing.

B[3]

Every major guideline states hormone therapy should not be used to prevent cardiovascular disease: NICE says do not offer it for primary or secondary CVD prevention, USPSTF grades preventive use a D recommendation, and a 2024 WHI investigators' review states the trials do not support hormone therapy to prevent cardiovascular disease.

A[4]A[5]A[6]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

No - use for symptoms and bone only, not heart prevention

NAMS 2022, NICE 2024, USPSTF 2022, and the WHI investigators

The WHI is the largest randomized dataset ever collected and did not show a statistically significant reduction in coronary heart disease even in the youngest stratum (CHD HR 0.76 in the under-10-years group, with the confidence interval crossing 1). NICE explicitly instructs clinicians not to offer hormone therapy for cardiovascular prevention, and USPSTF grades preventive use a D recommendation.

B[3]A[4]A[5]

Yes - early initiation is genuine cardiovascular and mortality prevention

field clinicians and lipid/atherosclerosis researchers in the corpus, including Dr. Howard Hodis and Dr. Wendy Mack, Dr. Avrum Bluming, Dr. Sharon Malone, and Dr. Felice Gersh

A meta-analysis restricted to women who started within 10 years of menopause found lower mortality (RR 0.70) and lower coronary heart disease (RR 0.52); a small open-label randomized trial (DOPS) starting therapy about 7 months after menopause found a composite of death, heart failure, or heart attack cut nearly in half (HR 0.48) over 10 years of treatment; and decades of concordant observational data point the same direction.

A[7]B[8]

What would settle it: A large randomized trial of modern hormone therapy (transdermal estradiol plus micronized progesterone) started within about 6 years of menopause, powered for hard cardiovascular endpoints and mortality over 10-plus years. No such trial currently exists or is running at scale.

What is really going on here

  1. Am I being quoted a relative risk or an absolute risk - how many women per 1,000 per year does that actually mean?
  2. If the goal is my heart, what does my clinician propose that has actually been proven - blood pressure, lipids, exercise, smoking - and what role, if any, is hormone therapy playing in that plan?

Questions for your doctor

  1. What is my absolute risk change in events per 1,000 women per year, not just the relative risk?
  2. How many years since my last period am I, and does that change the risk-benefit picture?
  3. What proven heart-protective steps (blood pressure, lipids, exercise, smoking) are part of my plan regardless of hormone therapy?
  4. Are you offering hormone therapy for symptoms and bone, or implying it will protect my heart?

Questions with no answer yet

Would a large, modern trial of transdermal estradiol plus micronized progesterone, started within about 6 years of menopause and followed for a decade or more, actually show a real reduction in heart attacks and strokes, or would it replicate the largely neutral result seen in the original large trial?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Both sides of this debate explicitly agree that this trial does not exist and is not currently running at scale. The case for cardioprotection currently rests on subgroups of an older trial, one small open-label trial, surrogate imaging measures, and decades of observational data, none of which is the same as a dedicated hard-endpoint trial.

What would test it: A large randomized trial of modern hormone therapy initiated within about 6 years of menopause, powered for hard cardiovascular endpoints and mortality over 10-plus years.

Is the absence of a dedicated cardioprotection trial in younger initiators a sign the field doesn't expect a benefit, or mainly a reflection that such a trial would be enormous, expensive, and commercially unattractive to fund?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: No sponsor has run this trial since the original large government-funded trial, which was not industry-funded. A modern equivalent would need to be very large and run for a decade or more to detect hard cardiovascular outcomes, exactly the kind of study that lacks an obvious commercial funder now that hormone therapy is largely off-patent.

What would test it: Public or foundation funding of the same large, modern, hard-endpoint trial described above; short of that funding materializing, the question will likely remain open indefinitely.

Sources

  1. 1.Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the WHI randomized controlled trial. JAMA. 2002;288(3):321-33. · Randomised trial
  2. 2.Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.Anderson GL, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the WHI randomized controlled trial. JAMA. 2004;291(14):1701-12. · Randomised trial
  3. 3.Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.Rossouw JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-77. · Randomised trial
  4. 4.NICE guideline NG23. Menopause: identification and management. November 2024 update, recommendation 1.6.4.Systematic review or guideline
  5. 5.Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement.US Preventive Services Task Force. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: USPSTF recommendation statement. JAMA. 2022;328(17):1740-1746. · Systematic review or guideline
  6. 6.The Women's Health Initiative Randomized Trials and Clinical Practice: A Review.Manson JE, et al. The Women's Health Initiative randomized trials and clinical practice: a review. JAMA. 2024;331(20):1748-1760. · Systematic review or guideline
  7. 7.Hormone therapy for preventing cardiovascular disease in post-menopausal women.Boardman HM, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;(3):CD002229. · Systematic review or guideline
  8. 8.Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial.Schierbeck LL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial (DOPS). BMJ. 2012;345:e6409. · Randomised trial

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides